Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb-IVB mycosis fungoides/Sézary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT)
Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb-IVB mycosis fungoides/Sézary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT)
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Δεν υπάρχει περίληψη
Έτος δημοσίευσης:
2021
Συγγραφείς:
Stadler, R. Romero, P.O. Bagot, M. Quaglino, P. Guenova, E. Jonak, C. Papadavid, E. Stranzenbach, R. Sartori, D. Musoro, J.Z. Falato, C. Marreaud, S. Scarisbrick, J.J. Knobler, R.
Περιοδικό:
European journal of cancer (Oxford, England : 1990)
